TESTS
PROSTOXTM
Our First Radiogenomics Test — PROSTOX
PROSTOX helps prostate cancer patients avoid toxicity from radiation therapy.
Our first microRNA-based test is for prostate cancer patients who are being offered stereotactic body radiation therapy (SBRT).
PROSTOX analyzes a patient's germline DNA to determine if the individual is at increased risk of late grade ≥2 genitourinary (GU) toxicity following radiation therapy. Some examples of such toxicity are urethral strictures (which result in difficult or painful urination) and hematuria (blood in the urine).
PROSTOX reports the risk of late GU radiation toxicity based on a patient’s mirSNP signature. The assay provides a risk score (low or high) that may be useful in guiding the safest course of treatment, which may be alternatives to SBRT, to avoid toxicity.
Learn more about PROSTOX:
Begin PROSTOX Testing
Would you like to join our clinics in using the PROSTOX test? Please contact us here to arrange a meeting.
Access for Patients
MiraKind is currently offering access to PROSTOX for patients who meet specific requirements. Learn more:
Publications-Radiogenomics and Prostate Cancer
- Kishan AU, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Network Open 2019;2:e188006.
- Weidhaas, JB, et al. MicroRNA-based biomarkers of the radiation response in prostate cancer. Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 163-163. DOI: 10.1200/JCO.2020.38.6_suppl.163.
- Kishan AU, et al. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Journal for Radiotherapy and Oncology 2022;167:226-232. doi: 10.1016/j.radonc.2021.12.040.